Risk of Recurrence by Nodal Status and High-Risk Features in Patients with HR+, HER2-, Early Breast Cancer: An Analysis of Real-world Data

被引：0
|
作者：
Grimes, B. [1 ]
Tolaney, S. M. [2 ]
Sammons, S. [2 ]
Cortes, J. [3 ,4 ]
Liepa, A. M. [1 ]
Sugihara, T. [5 ]
Cui, Z. Lin [1 ]
Gathirua-Mwangi, W. [1 ]
Shahir, A. [1 ]
Monaco, M. [1 ]
Neven, P. [6 ]
Johnston, S. [7 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[3] Quironsalud Grp, Inst Int Breast Canc Ctr, Dept Med, Pangaea Oncol, Barcelona, Spain
[4] Univ Europea Madrid, Fac Biomed & Hlth Sci, Madrid, Spain
[5] Syneos Hlth, Morrisville, NC USA
[6] Univ Hosp Leuven, Louvain, Belgium
[7] Royal Marsden NHS Fdn Trust, London, England
来源：
BREAST | 2025年 / 80卷
关键词：
D O I：
10.1016/j.breast.2025.103897
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P003
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Factors associated with distant recurrence (DR) risk in patients (pts) with HR+/HER2-early breast cancer (EBC): a machine learning (ML) model-based analysis using real-world (RW) data
    Sparano, J. A.
    Lustberg, M. B.
    de Nonneville, A.
    Bachelot, T.
    Santa-Maria, C. A.
    Blyuss, O.
    Fasching, P. A.
    Brezden-Masley, C.
    Park, Y. H.
    Akdere, M.
    Ye, F.
    Pattipaka, T.
    Manneni, V. R.
    Kurz, C.
    Castro, P. Dominguez
    Howard, F. M.
    BREAST, 2025, 80
  • [22] Treatment Patterns and Health Resource Utilization in Patients With HR+/ HER2- Locally Advanced or Metastatic Breast Cancer in Real-World Setting in Taiwan
    Novick, Diego
    Rajan, Narayan
    Wei, Alice
    Cheng, Rebecca
    Colman, Sam
    Szende, Agota
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 36 : 98 - 104
  • [23] Abemaciclib Improves Disease-Free Survival in High-Risk HR+/HER2-Early Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S5 - S6
  • [24] Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study
    D. Johnston, Stephen R.
    Rugo, Hope S.
    Tolaney, Sara M.
    Fernandez, Maria Munoz
    Wei, Ran
    Martin, Miguel
    FUTURE ONCOLOGY, 2024, 20 (28) : 2037 - 2048
  • [25] Metastatic HR+/HER2-Breast Cancer Real-World Data support the clinical Benefits of Palbociclib
    Schoellmann, Claudia
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [26] Clinicopathological and molecular features of HR+/HER2- breast cancer patients with distinct endocrine resistance patterns
    Zhang, Siwei
    Wang, Han
    Zhang, Hang
    Zhuang, Qingyuan
    Zhu, Xiaohui
    Xiao, Yi
    Jiang, Yizhou
    CHINESE JOURNAL OF CANCER RESEARCH, 2025, 37 (01)
  • [27] Adjuvant Therapy of HR+, HER2 Breast Cancer Prolonging Survival without invasive Disease in high-risk early Breast Cancer
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (7-8)
  • [28] Fulvestrant in clinical practice: Effectiveness analysis in Uruguayan patients with HR+/HER2- breast cancer
    Camejo, Natalia
    Amarillo, Dahiana
    Castillo, Cecilia
    Alza, Sofia Badia
    Balino, Camila
    Banchieri, Miguel
    Fagundez, Juan
    Ghiga, Santiago
    Lorier, Marcos
    Alonso, Isabel
    Waltier, Gabriel David Krygier
    MEDWAVE, 2024, 24 (08):
  • [29] Real-world study of patients with HR+/ HER2-metastatic breast cancer treated with palbociclib and fulvestrant
    Robert, Nicholas
    Chen, Connie
    Doan, Justin
    Venkatasetty, Divea
    Espirito, Janet L.
    Aguilar, Kathleen M.
    FUTURE ONCOLOGY, 2025, 21 (01) : 83 - 94
  • [30] Real-world outcomes in metastatic HR+/HER2-, HER2+and triple negative breast cancer after start of first-line therapy
    DeClue, Richard W.
    Fisher, Maxine D.
    Gooden, Kyna
    Walker, Mark S.
    Le, Trong Kim
    FUTURE ONCOLOGY, 2023, 19 (13) : 909 - 923
12345